Cowen & Co. Maintains a Hold Rating on United Therapeutics (UTHR)


Cowen & Co. analyst Chris Shibutani maintained a Hold rating on United Therapeutics (UTHR) today and set a price target of $106. The company’s shares opened today at $111.04.

According to TipRanks.com, Shibutani is a 1-star analyst with an average return of -2.0% and a 35.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for United Therapeutics with a $142.40 average price target, implying a 28.2% upside from current levels. In a report issued on November 1, H.C. Wainwright also reiterated a Hold rating on the stock with a $95 price target.

.

See today’s analyst top recommended stocks >>

United Therapeutics’ market cap is currently $4.84B and has a P/E ratio of 8.95. The company has a Price to Book ratio of 1.80.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.

Read More on UTHR:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts